Study of aspirin and anaemia risk in healthy older adults
Update contact details
View publications library
ASPREE results summary
THE ASPREE PROJECT
Aspirin and Ageing Health Research
Populations around the world are ageing. The ASPREE project is a long-term multi-centre, bi-national study of aspirin and health in older adults, with the purpose to discover ways to maintain health, quality of life and independence as we age.
This landmark research has two components:
1) ASPREE (ASPirin in Reducing Events in the Elderly), a randomised, blinded, placebo-controlled clinical trial of low-dose (100mg) aspirin in healthy older adults. The trial’s ground-breaking findings underpin revised international aspirin prescribing guidelines.
2) ASPREE-XT (ASPREE – eXTension) study, an ongoing, follow-up observational health study to investigate long-lasting effects of low-dose aspirin on disease, such as cancer. Additionally, it investigates a broad range of factors that contribute to the maintenance of physical and cognitive health in older adults.
Findings from the ASPREE project advance the care and wellbeing of ageing adults around the world.
All participants – 16,703 in Australia (aged 70+ years) and 2,411 in the U.S. (minorities aged 65+ years) – were free of dementia, significant physical disability and known cardiovascular disease at enrolment.
The ASPREE Project is funded by the Australian and U.S. governments and is led by Monash University in Australia and the Berman Centre for Outcomes and Clinical Research in the United States.
Thanks to the support of participants during the ASPREE project, multiple sub-studies have provided and will continue to provide, invaluable information on aspects of health and ageing.
ASPREE Trial Results
In September 2018, the ASPREE trial published results in three separate papers in one edition of the prestigious New England Journal of Medicine.
Translation into Care
The American College of Cardiology and American Heart Association adopted ASPREE findings into their revised primary prevention aspirin guidelines.
ASPREE-XT is an important follow up study into demographic, health, genomic and environmental factors that contribute to healthy ageing.
Page updated: 1 March 2021
A new analysis of ASPREE trial data has found that prolonged daily aspirin use increases the risk of anaemia in some older adults. Findings from ASPREE-Anaemia, a sub-study of the ASPREE trial, may help GPs identify older patients at higher risk of anaemia and who may benefit from regular monitoring for development of the condition.
Walking speed and grip strength could be early indicators of dementia before the onset of noticeable symptoms, new findings from the ASPREE trial reveals. Researchers found slow walking speed combined with weak hand grip was a stronger predictor of cognitive decline and dementia in older adults than either measure alone.
A post with links to more information about studies summarised in the latest ‘TABLET’ (Winter_Spring 2022) participant newsletter.